A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome.
The effect of spironolactone in the alleviation of the symptoms of the premenstrual syndrome was compared with placebo in a double-blind, parallel group controlled study. One tablet daily of 100 mg spironolactone or placebo was given to 63 women from Day 12 of the menstrual cycle until the first day of the next menstrual bleed. This regimen was repeated for two consecutive cycles. Spironolactone was statistically significantly superior in providing relief from bloatedness (p less than 0.001). No statistically significant changes were observed in blood biochemistry of plasma hormone levels of oestradiol, progesterone or prolactin, though an increase in serum aldosterone levels was seen in the spironolactone-treated group. No differences were detected in weight, blood pressure or the incidence and severity of complaints following treatment.
D000328:Adult; D000450:Aldosterone / Q000097:blood; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D010352:Patient Dropouts; D011293:Premenstrual Syndrome / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D011897:Random Allocation; D013148:Spironolactone / Q000627:therapeutic use*
D013148:Spironolactone; D000450:Aldosterone